Summary
Immunohistochemistry (IHC) is a powerful technique that exploits the specific binding between an antibody and antigen to detect and localize specific antigens in cells and tissue, most commonly detected and examined with the light microscope. A standard tool in many fields in the research setting, IHC has become an essential ancillary technique in clinical diagnostics in anatomic pathology (1) with the advent of antigen retrieval methods allowing it to be performed conveniently on formalin fixed paraffin embedded (FFPE) tissue (2, 3) and automated methods for high volume processing with reproducibility (4). IHC is frequently utilized to assist in the classification of neoplasms, determination of a metastatic tumor’s site of origin and detection of tiny foci of tumor cells inconspicuous on routine hematoxylin and eosin (H&E) staining. Furthermore, it is increasingly being used to provide predictive and prognostic information, such as in testing for HER2 amplification in breast cancer (5) in addition to serving as markers for molecular alterations in neoplasms, including IDH1 and ATRX mutations in brain tumors (6). In this section we describe the basic methods of immunohistochemical staining which has become an essential tool in the daily practice of anatomic pathology worldwide.
Cancer affects millions of individuals worldwide. One shortcoming of traditional cancer classification systems is that, even for tumors affecting a single organ, there is significant molecular heterogeneity. Precise molecular classification of tumors could be beneficial in personalizing patients' therapy and predicting prognosis. To this end, here we propose to use molecular signatures to further refine cancer classification. Molecular signatures are collections of genes characterizing particular cell types, tissues or disease. Signatures can be used to interpret expression profiles from heterogeneous samples. Large collections of gene signatures have previously been cataloged in the MSigDB database. We have developed a web-based Signature Visualization Tool (SaVanT) to display signature scores in user-generated expression data. Here we have undertaken a systematic analysis of correlations between inflammatory signatures and cancer samples, to test whether inflammation can differentiate cancer types. Inflammatory response signatures were obtained from MsigDB and SaVanT and a signature score was computed for samples associated with 7 different cancer types. We first identified types of cancers that had high inflammation levels as measured by these signatures. The correlation between signature scores and metadata of these patients (sex, age at initial cancer diagnosis, cancer stage, and vital status) was then computed. We sought to evaluate correlations between inflammation with other clinical parameters and identified four cancer types that had statistically significant association (pvalue < 0.05) with at least one clinical characteristic: pancreas adenocarcinoma (PAAD), cholangiocarcinoma (CHOL), kidney chromophobe (KICH), and uveal melanoma (UVM). These results may allow future studies to use these approaches to further refine cancer subtyping and ultimately treatment.
1516 Abstract 17 Cancer affects millions of individuals worldwide. One shortcoming of traditional cancer 18 classification systems is that, even for tumors affecting a single organ, there is significant 19 molecular heterogeneity. Precise molecular classification of tumors could be beneficial in 20 personalizing patients' therapy and predicting prognosis. To this end, here we propose to 21 use molecular signatures to further refine cancer classification. Molecular signatures are 22 collections of genes characterizing particular cell types, tissues or disease. Signatures can 23 be used to interpret expression profiles from heterogeneous samples. Large collections of 24 gene signatures have previously been cataloged in the MSigDB database. We have 25 developed a web-based Signature Visualization Tool (SaVanT) to display signature 26 scores in user-generated expression data. Here we have undertaken a systematic analysis 27 of correlations between inflammatory signatures and cancer samples, to test whether 28 inflammation can differentiate cancer types. Inflammatory response signatures were 29 obtained from MsigDB and SaVanT and a signature score was computed for samples 30 associated with 7 different cancer types. We first identified types of cancers that had 31 high inflammation levels as measured by these signatures. The correlation between 32 signature scores and metadata of these patients (gender, age at initial cancer diagnosis, 33 cancer stage, and vital status) was then computed. We sought to evaluate correlations 34 between inflammation with other clinical parameters and identified four cancer types that 35 had statistically significant association (p-value < 0.05) with at least one clinical 36 characteristic: pancreas adenocarcinoma (PAAD), cholangiocarcinoma (CHOL), kidney 37 chromophobe (KICH), and uveal melanoma (UVM). These results may allow future 3 38 studies to use these approaches to further refine cancer subtyping and ultimately 39 treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.